# Bristol-Myers Squibb: Phase 1 study terminated, 34 enrolled (Acute Myeloid Leukemia, Myelodysplastic Syndrome)

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| NCT ID | NCT06419634 |
| Phase | Phase 1 |
| Status | terminated |
| Conditions | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
| Intervention types | drug |
| Target enrollment | 34 |
| Site countries | United States, Canada, Spain |
| Posted | 2024-05-17 |
| Planned start | 2024-05-29 |
| Event | Terminated |
| Event date | 2026-08-28 |
| Last update posted | 2026-10-01 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06419634). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.